Related Experiment Video
Updated: Aug 15, 2026
Translating Extracellular Electron Transfer Activities with Organic Electrochemical Transistors
Published on: January 31, 2025
Technology evaluation: Onyvax-P, Onyvax
Christian Doehn1, Torsten Böhmer, Dieter Jocham
1University of Lübeck Medical School, Department of Urology, Lübeck, Germany. doehn@medinf.mu-luebeck.de
Abstract:
Onyvax is developing Onyvax-P, an allogeneic whole-cell vaccine, for the potential treatment of prostate cancer. The vaccine is currently undergoing phase II clinical trials.
Insights
Onyvax-P is an allogeneic whole-cell vaccine being developed for prostate cancer treatment. This novel therapy is currently progressing through phase II clinical trials to evaluate its efficacy and safety.
Area of Science:
- Oncology
- Immunotherapy
- Vaccinology
Background:
- Prostate cancer remains a significant global health challenge.
- Current treatment options for advanced prostate cancer have limitations.
- There is a need for novel therapeutic strategies, including cancer vaccines.
Purpose of the Study:
- To evaluate the safety and efficacy of Onyvax-P, an allogeneic whole-cell vaccine, for prostate cancer treatment.
- To assess the potential of Onyvax-P as a novel immunotherapy approach.
Main Methods:
- Onyvax-P is an allogeneic whole-cell vaccine.
- The vaccine is derived from non-human cells.
- Clinical trials are being conducted to assess its therapeutic potential.
Main Results:
- The abstract does not contain specific results as the vaccine is in phase II clinical trials.
- Further data will be generated from ongoing clinical studies.
Conclusions:
- Onyvax-P represents a promising investigational therapy for prostate cancer.
- Phase II clinical trials are crucial for determining the vaccine's clinical utility.
